Details for New Drug Application (NDA): 021756
✉ Email this page to a colleague
The generic ingredient in MACUGEN is pegaptanib sodium. Additional details are available on the pegaptanib sodium profile page.
Summary for 021756
Tradename: | MACUGEN |
Applicant: | Bausch And Lomb Inc |
Ingredient: | pegaptanib sodium |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INTRAVITREAL | Strength | EQ 0.3MG ACID/0.09ML | ||||
Approval Date: | Dec 17, 2004 | TE: | RLD: | Yes |
Expired US Patents for NDA 021756
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription